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A B S T R A C T
The autosomal recessive non-syndromic hearing loss (ARNSHL) can be associated with variants in solute carrier
family 26, member 4 (SLC26A4) gene and is the second most common cause of ARNSHL worldwide. Therefore,
this study aims to determine the contribution of the SLC26A4 genotype in the hearing loss (HL) of 40 ARNSHL
pedigrees in Iran. A cohort of the 40 Iranian pedigrees with ARNSHL, having no mutation in the GJB2 gene, was
selected. The linkage analysis with ﬁve short tandem repeat (STR) markers linked to SLC26A4 was performed for
the 40 ARNSHL pedigrees. Then, two out of the 40 pedigrees with ARNSHL that linked to DFNB4 locus were
further screened to determine the variants in all exons of SLC26A4 gene by direct DNA sequencing. The 21 exons
of SCL26A4 were analyzed for the two pedigrees. A known variant (c.716T>A homozygote), it is the ﬁrst
reported incidence in Iran, a novel variant (c.493A>C homozygote) were detected in the two pedigrees and
pathogenesis of c.493A>C conﬁrmed in this study with review 100 hearing ethnically matched controls by
PCR-RFLP analysis. The present study suggests that the SLC26A4 gene plays a crucial role in the HL occurring in
Iranian pedigrees. Also, the results probably support the speciﬁcity and unique spectrum of SLC26A4 variants
among Iranian HL patients. Molecular study of SLC26A4 gene may lead to elucidation of the proﬁle of the
population-speciﬁc variants which has importance in diagnostics of HL.
1. Introduction
Hearing loss (HL) is a common sensorineural disorder, with an in-
cidence of one in every 500–1000 children [1,2]. At least half of the HL
cases can be attributed to genetic factors and more than two-thirds of
these individuals are classiﬁed as the autosomal recessive non-syn-
dromic hearing loss (ARNSHL). HL may be caused either by unknown
genetic factors or environmental factors [3], including pregnancy and
childbirth trauma, vitamin B deﬁciency during pregnancy, immuniza-
tion, bacterial infectious diseases such as meningitis, or a viral disease
such as rubella [4]. Since HL is extremely heterogeneous, studying
large-sized families from diﬀerent ethnicities, such as the Middle
Eastern populations, are helpful [5].
Based on several investigations, it is observed that the variants of
SLC26A4 gene are the second most common cause of ARNSHL, after
GJB2 mutations, in the world and that includes Iran [6]. These variants
are also known to be the most common detectable cause of an enlarged
vestibular aqueduct [2]. Pendrin is a protein that in humans is encoded
by the SLC26A4 gene. It is a 110 kDa glycosylated protein, which
functions as a membrane carrier protein that transports particles, such
as chloride, iodide, bicarbonate, oxalate, sulfate, and secondary active
sulfate across cell membranes [7].
Pendrin exists in diﬀerent organs and tissues, such as the kidneys,
liver, and the lining of airways, especially the inner ear and thyroid
gland. In the inner ear, it is likely that this protein helps control and
regulates the chloride and bicarbonate exchange [8]. Apart from
maintaining the required ionic levels for development of the inner ear,
it is believed that pendrin also inﬂuences the shape of the bony struc-
tures during this developmental phase [6].
The variants of SLC26A4 gene cause non-syndromic recessive HL
and Pendred syndrome (deafness with goiter, OMIM # 274600). To
date, over 170 diﬀerent alterations have been identiﬁed in SLC26A4
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(http://www.healthcare.uiowa.edu/labs/pendredandbor/slcMutations.
htm). The variant proﬁle and allele frequency may vary among dif-
ferent populations. The hotspot mutation in HL genes is mainly single-
gene biallelic mutation [9]. The SLC26A4 gene appears to have a more
important role in the etiology of HL in the Middle East and Asia than in
other parts of the world [10]. The determination of SLC26A4 mutations
in diﬀerent ethnic populations can provide new insights into the genetic
causes of HL, thus enabling better prognostication and enhanced
planning of management measures.
2. Materials and methods
2.1. Subjects
In this experimental study, the 40 Iranian pedigrees and each ped-
igree had at least 3 to 7 families. These families including 130 HL
individuals with the ARNSHL were that these pedigrees were selected
from>400 Iranian HL pedigrees with autosomal recessive syndromic,
autosomal dominant, X-linked recessive and mitochondrial. Also, there
were not patients suspected to show Pendred syndrome-like symptoms
in the 400 families with HL not involved in this study. At least two
aﬀected individuals with HL were existed in each pedigree. All cases
were negative for GJB2 mutations in our previous study (submitted).
All pedigrees had positive history of HL and were of Kurdish eth-
nicity. Also, for pathogenicity study 100 ethnically matched hearing
controls were recruited. A written informed consent had been provided
for all the patients in our previous study [11]. After ﬁlling out an in-
formed consent form by subjects or their parents (children under age
18) about 5ml of peripheral blood from all the ARNSHL pedigree
members was collected in tubes containing EDTA (0.5 M).
Based on the interviews with the adult members of the pedigrees,
informational questionnaires had been ﬁlled out and pedigrees drawn.
Table 1
The STR markers of DFNB4 (SLC26A4) (107,660,635–107,717,809) and their primer sequences. The version of human genomic reference sequence (GRCh38/hg38).
Reverse primer sequence (R)a Forward primer sequence (F)b PCR
product
(bp)
Location
(decode cM)
Location
(Genethon
cM)
Location
(Marshﬁed
cM)
Length position (bp) STR
AAATAATGACTGAGGCTCAAAACA CCTGTATGGAGGGCAAACTA 240–290 116 120.70 119.81 106,889,928– 106,890,211 D7S2420
GCTATAACCTCATAANAAACCAAAA AACAACAGTCAACCCACAAT 129–141 117.04 120.70 119.81 107,414,241–107,614,405 D7S496
CCGCCTTAGTAAAACCC AAGAAGTGCATTGAGACTCC 140–152 117.72 120.70 119.81 107,331,501–107,331,642 D7S2459
ACAGGGGTCTCTCACACATATTA CTGGAAATTGACCTGAAACCTT 238–252 118.39 121.50 120.61 107,683,218–107,683,460 D7S2456
CCTGTTTCAGATGTTTTATCC CTAGTCCTGAGAAGACATTACCC 240–290 118.39 121.5 121.41 108,606,555–108,806,907 D7S2425
a Reverse.
b Forward.
Fig. 1. The haplotype analysis of the pedigree IR-15 is shown in up ﬁgure and being linked to the D7S2420 marker of the SLC26A4 gene is detected by the 15%
polyacrylamide gel at this pedigree in down ﬁgure. The healthy individuals were heterozygous (1/2) and homozygous (2/2); three patients were homozygous (1/1).
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This study was approved by the Institutional Review Boards of the
Shahrekord University of Medical Sciences, Shahrekord, Iran, in 2016
(Grant No. 2165). Two consanguineous pedigrees from Kurdistan
(pedigree IR-15) and Kermanshah (pedigree IR-48) provinces of Iran,
with three and two HL patients, respectively, linked to DFNB4 locus
were further studied.
For all cases, pure-tone audiometric test (PTA) for air and bone
conduction at frequencies 250 to 8000 Hz was performed to clarify HL
severity as follows: mild: 21–45 dB; moderate: 46–60 dB; moderately
severe: 61–75 dB; severe: 76–96 dB; and profound: ≥97 dB. Also, HL
severity of all patients with conventional auditory brainstem response
(ABR) testing was performed by certiﬁed audiologists (which are not
shown in this study).
In general, a complete clinical evaluation including audiological,
physical examinations, and ophthalmological was done to exclude
environmental exposures and to detect the presence of Syndromic re-
sults in each pedigree. For the all patients of the linked pedigrees by
temporal bone CT-scan was conducted using Somatom Sensation
Emotion 16 — Slice Conﬁguration (Siemens Medical Solutions,
Erlangen, Germany) to clarify the vestibular aqueduct situation.
According to this experiment was not observed enlarged vestibular
aqueduct (EVA) in patients.
For assessing thyroid phenotype in all patients of the two pedigrees,
thyroid-stimulated hormone (TSH), thyroxin (T4) and triiodothyronine
(T3) levels were measured using a chemiluminescent immunoassay
(Berthold Technology-CSA, Germany). Also ultrasonography was per-
formed with a Sonoline G50 ultrasound system (Siemens Medical
Solutions, Erlangen, Germany) to determine the thyroid size in all pa-
tients. Thyroid ultrasonography and hormone investigation results were
interpreted according to sex and age of patients and these results were
Fig. 2. Electropherograms from the normal (a), the c.716T>A (p.V239D) homozygous (b), normal (c), and the c.493A>C (p.S165R) homozygous (d) genotypes are
shown. Arrows show the location of the base change.
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normal in all patients of the two pedigrees.
2.2. DNA extraction
DNA for all available members of the pedigrees, and normal controls
was extracted using a DNA extraction kit (DNPTM, CinnaGen, Tehran,
Iran). The DNA concentration and absorbance ratios were tested with
the Nanodrop spectrophotometer (Thermo Scientiﬁc NanoDrop 1000
Spetrophotometer, Thermo Scieniﬁc, Wilmington, USA).
2.3. Genetic analysis of GJB2 and SLC26A4
Using sequence analysis, the 40 pedigrees were examined for mu-
tations in the GJB2 gene. Pedigrees who did not possess mutation in this
gene were then isolated (40 out of 50 the Iranian deaf pedigrees). Based
on a previous study (submitted), these GJB2 negative pedigrees were
screened for linkage to DFNB4 by genotyping the short tandem repeat
(STR) markers (Table 1). The linkage analysis was followed by se-
quencing of SLC26A4 for two linked pedigrees.
2.4. Ampliﬁcation of the STR markers and linkage analysis
Power of the 40 pedigrees for linkage analysis was carried out by
evaluating SLINK, using the Fast Slink (version 2.51) option of Easy
Linkage plus version 5.05 software [12]. STR markers and primers were
selected based on NCBI Map Viewer and UniSTS data. LOD scores of
two-point and multi-point were calculated using Super Link (version
1.6) and Gene hunter (version 2.91). For the LOD calculation, complete
penetrance, autosomal recessive inheritance, disease allele frequency of
0.001, no phenocopies, and equal recombination frequencies for both
males and females were assumed. Moreover, the reconstruction of
haplotypes was done by Haplopainter software (version 029.5) (Fig. 1)
[13].
Polymerase chain reaction (PCR) was applied for ampliﬁcation of
the ﬁve DFNB4 STR markers. The ampliﬁed conditions were as follows:
reaction volume of 15 μl with a ﬁnal concentration of ddH2O 7.5 μl,
master mix 5.5 μl, forward primer (20 pmol/μl) 0.5 μl, reverse primer
(20 pmol/μl) 0.5 μl, and template genomic DNA (100 ng/μl) 1 μl. The
thermal cycle proﬁle for PCR was performed using a thermal cycler
(Program Temp Control System PC-700, ASTEC, Fukuoka, Japan) with
the protocol as follows: an initial denaturation step of 1min at 95 °C,
followed by 30–35 cycles of 1min of denaturation at 95 °C, 24 s of an-
nealing for diﬀerent markers at 51–59 °C, and a 35-s extension at 72 °C;
with a ﬁnal 8-min extension at 72 °C [14]. PCR amplicons were ana-
lyzed on a 15% polyacrylamide gel electrophoresis (PAGE) (Fig. 1).
2.5. Mutation analysis of SLC26A4 gene by sequencing analysis
In the two Iranian linked pedigrees with ARNSHL, the sequencing of
21 exons and exon-intron boundaries of SLC26A4 gene was done using
speciﬁcally designed primers [15]. The ampliﬁcation conditions were
as follows: reaction volume was 15 μl with a ﬁnal concentration of
7.5 μl, master mix 5.5 μl, forward primer (20 pmol/μl) 0.5 μl, reverse
primer (20 pmol/μl) 0.5 μl, and template genomic DNA 1 μl (100 ng/μl).
The thermal cycle proﬁle for PCR (Program Temp Control System PC-
700, ASTEC, Fukuoka, Japan) was as follows: initial denaturation step
of 5-min at 95 °C, followed by 32–33 cycles of 30 s at 95 °C, annealing of
30-s for diﬀerent primers at 54–63 °C, and a 24-s extension at 72 °C,
Fig. 3. The haplotype analysis of the pedigree IR-48 with the novel variant
c.493A>C was shown and the results of the co-segregation is determined for
this variant.
Fig. 4. Pure tone audiometry is shown of the two probands with the two SLC26A4 variants (c.493A>C and c.716T>A).
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with a ﬁnal extension for 5-min at 72 °C. The sequencing was carried
out at in SEQLAB (Sequence Laboratories, Gottingen, Germany)
(Fig. 2).
2.6. Conﬁrmation of pathogenicity for c.493A>C
The pathogenicity study was based on the co-segregation (the pre-
sence of the homozygous variant in patients and its absence or het-
erozygosity in the non-aﬀected family members) (Fig. 3), absence or
heterozygosity of variants in at least 100 hearing ethnically matched
controls using PCR-RFLP analysis. The restriction enzyme Aci1 was
selected for PCR-RFLP analysis, using NEBCutter (http://tools.neb.
com/NEBcutter2/). A 689 bp length fragment of exon 5 containing
c.493A>C site was ampliﬁed in 100 ethnically matched normal con-
trols and all available members of the IR-48 pedigree.
PCR amplicons were analyzed on a 10% polyacrylamide gel elec-
trophoresis (PAGE). The wild and mutant alleles have one and two Aci1
cutting site, respectively. After digestion, the normal allele had 605 bp
and 84 bp, but the mutant allele had 365 bp, 240 bp, and 84 bp frag-
ments. In c.493A>C variant serine (polar without charge) in this po-
sition is replaced by arginine (polar with positive charge), that this
diﬀerence in the load can, to some extent, enhance the pathogenicity of
this variant.
3. Results
3.1. The audiological data of SLC26A4 mutation patients
All patients of pedigrees IR-15 and IR-48 had bilateral profound HL
(≥97 dB) (Fig. 4).
3.2. Radiological information of temporal bone
The enlarged vestibular aqueduct (EVA) was not observed in the
patients from the two pedigrees.
3.3. Thyroid status
All of the patients from the two pedigrees had normal TSH, T4, T3
hormone levels, and thyroid size.
3.4. Family data
In the current research, the 40 pedigrees with at least two the
ARNSHL patients with negative GJB2 mutation were selected for in-
vestigation. All related conditions with ARNSHL were evaluated by
physical examination and audiology tests to discriminate ARNSHL from
age-related HL. Mainly, the two pedigrees showed linkage to the DFNB4
locus.
3.5. SLINK and linkage analysis results
SLink value theoretically predicts the LOD score for a pedigree.
SLink, two-point and multi-point LOD scores were 1.33, 1.32, and 1.4
for the pedigree IR-15 and 0.72, 0.73 and 0.72 for the pedigree IR-48,
predicting possible linkage to the DFNB4 locus.
3.6. SLC26A4 sequence analysis result
The molecular analysis of the SCL26A4 variants in patients of the
linked pedigrees revealed a known pathogenic variant (c.716T>A
homozygote) in exon 6 for the pedigree IR-15, and a novel pathogenic
variant (c.493A>C homozygote) was in exon 5 for the pedigree IR-48.
All patients were homozygous and individuals: I.1, I.2, II.1, II.4, and II.5
were heterozygous for variant c.716T>A in the pedigree IR-15. Also,
the all patients were homozygous and the individuals: I.1, I.2, and II.3Ta
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were heterozygous for variant c.493A>C (p.S165R) in the pedigree IR-
48.
The c.716T>A (p.V239D) variant had earlier been reported in a
Palestinian family as a novel mutation. Interestingly, in the Iranian
ARNSHL population, this was detected for the ﬁrst time during the
present investigation. Also in this study, there were the ﬁve novel
variants and the two known variants detected as polymorphisms in
these two pedigrees (Table 2). In silico analysis predicted their im-
portance in combination with other pathogenic alleles.
3.7. Mutation conﬁrmation analysis
The c.493A>C variant was not detected in the 100 ethnically
matched control individuals, without HL and segregated with the dis-
ease in the pedigree. In the c.493A>C variant serine (polar without
charge) in this position is replaced by arginine (polar with positive
charge), which may cause the defects in folding of the protein. These
results suggest that the c.493A>C variant is most likely to be pa-
thogen. Furthermore, this c.493A>C variant was pathogenic in this
study.
4. Discussion
Our data suggests that the SLC26A4 pathogenic variants constitute
(2 out of the 50 Iranian deaf pedigrees) 4% of the etiology of the
ARNSHL in Iran that may be involved in the severity of HL, and the
phenotype may be modiﬁed by epistatic interactions. In the present
research, all the pedigrees were bilateral and all of the patients had
profound sensorineural HL.
The linkage analysis and haplotype analysis for the DFNB4 locus
revealed linkage in the two pedigrees. The DNA sequencing of SLC26A4
in all aﬀected individuals of these linked pedigrees led to the identiﬁ-
cation of the ﬁve diﬀerent homozygous variants: (c.493A>C and
c.716T>A) were the pathogenic variants and c.416-114A>G,
g.28351T>A, and c.1001+131G>T( were the polymorphism var-
iants. The novel variants, (g.862T>A, heterozygote), (c.493A>C,
homozygote), (g.13368G>A, heterozygote), (g.28351T>A, hetero-
zygote), (g.28375G>A, heterozygote), and (g.34248G>C,
heterozygote) as well as the known variants (g.23034G>T, homo-
zygote), and (g.13416A>G, homozygote) are the polymorphism var-
iants and typically found in ARNSHL.
In this study, we detected a novel variant (c.493A>C) that linked
to DFNB4 in an Iranian pedigree. It is in the CDS region of exon 5; the
key feature of this variant is its topological domain which is in an ex-
tracellular local between the third and fourth transmembrane domains
of the pendrin homozygote. In the c.493A>C variant serine (polar
without charge) in this position is replaced by arginine (polar with
positive charge). Therefore, it is possible for the substitution to detect
an eﬀect on the structure, charge and function of the protein. Moreover,
running Consurf server (https://www.ncbi.nlm.nih.gov/Structure/cdd/
wrpsb.cgi) was determined a rather high conservation score for serine
at position 165 (Fig. 5). This is the reason of rather high conservation
degree of serine 165 among orthologs. (Polyphen prediction=1
[−14 < conserves < +6] and PhastCons prediction= 0.04
[0 < conserves < 1]) (http://mutationtaster.org).
The c.716T>A variant is as a transversion mutation in exon 6 that
valine (nonpolar and without charge) and in this position is replaced by
aspartic acid (polar with negative charge) and highly conserved
(Polyphen prediction=3.021 and PhastCons prediction= 0.984)
(http://mutationtaster.org), is known to cause changes in the ﬁfth and
sixth transmembrane domains of the third extracellular loop in pendrin
(Fig. 6). Valine in this position is conserved in Mus musculus, Rattus
norvegicus and Homo sapiens [16]. According, these variations are in
exons and highly conserved, therefore, it is possible for the substitutions
to alter the structure and function of the protein and this may enhance
the pathogenicity. The cause of the HL in the remaining pedigrees does
not detect to be related to mutations in SLC26A4 and other unidentiﬁed
loci may be involved, though environmental factors could not be fully
in creation HL. The present research detected the c.716T>A variant in
the Iranian ARNSHL population for the ﬁrst time. It had previously been
reported as a novel mutation in a Palestinian family [17].
The c.716T>A pathogenic variant was found in 16 Pakistani fa-
milies and haplotype analyses suggested that it is a founder variant. The
families with the c.716T>A variant had an inherited autosomal re-
cessive early-onset, sensorineural HL [18]. The c.716T>A variant in
the pendrin protein is associated with a signiﬁcant decrease in the
transportation activity. Moreover, it is assumed that the residual func-
tion of pendrin with c.716T>A could be improved by an activator of
pendrin [19].
Studies reported folding-defective pendrin protein (with
c.716T>A) is retained in the endoplasmic reticulum [17]. Ad-
ditionally, this functional malfunction may be caused by unidentiﬁed
factors, proteins and modiﬁer genes [20]. The frequency of this variant
varies worldwide, from 5% in the Middle East and South Asia to 0% in
Africa [21]. The assumed founder eﬀect of the c.716T>A variant is in
the Middle East (30% of the mutant alleles of SLC26A4 are in Pakistan)
[18]. However, future investigations are required to conﬁrm this hy-
pothesis. In the present study, the frequency of this mutation in the
Fig. 5. The result of the p.S165R conservation investigation using consurf database. (S) 165 amino acid is shown with arrow.
Fig. 6. The location of the SLC26A4 variants on the protein.
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Iranian pedigrees with ARNSHL was 2%. Diﬀerent studies have de-
tected at least 200 variants in the SLC26A4 gene and this gene is known
as the second most common cause of ARNSHL in the world [21].
5. Conclusion
Despite many studies conducted on the role of SLC26A4 in HL, the
spectrum and frequency of its diﬀerent mutations remain to be accu-
rately exposed for the diﬀerent ethnic groups. This is probably due to
the allelic heterogeneity, the large size of SLC26A4, racial diversity, and
the large number of known and unknown mutations occurring across
this gene. However, these studies help in clinical decision-making, ge-
netic counseling, and a suitable treatment strategy for ARNSHL pa-
tients.
Financial support and sponsorship
This study was ﬁnancially supported by the research deputy of the
Shahrekord University of Medial Sciences (grant: 2165). The research
also was approved by the ethics committee of Shahrekord University of
medical sciences with a number: IR.SKUMS.REC.1395.105.
Conﬂicts of interest
The authors have declared that no competing interests exist. All
authors have approved this manuscript.
Acknowledgements
The authors gratefully acknowledge all the Kurdish families and
staﬀ of the Molecular Research Center who participated in this re-
search.
References
[1] Mahmoudian-Sani M-R, Mehri-Ghahfarrokhi A, Ahmadinejad F, et al. MicroRNAs:
eﬀective elements in ear-related diseases and hearing loss. Eur Arch
Otorhinolaryngol 2017;274(6):2373–80.
[2] Ahadizadeh E, Ascha M, Manzoor N, et al. Hearing loss in enlarged vestibular
aqueduct and incomplete partition type II. Am J Otolaryngol 2017;38(6):692–7.
[3] Singer AEA, Abdel-Naby Awad OG, El-Kader RMA, et al. Risk factors of sensor-
ineural hearing loss in patients with unilateral safe chronic suppurative otitis media.
Am J Otolaryngol 2018;39(2):88–93.
[4] Lanzieri TM, Dollard SC, Bialek SR, et al. Systematic review of the birth prevalence
of congenital cytomegalovirus infection in developing countries. Int J Infect Dis
2014;22:44–8.
[5] Brownstein Z, Friedman LM, Shahin H, et al. Targeted genomic capture and mas-
sively parallel sequencing to identify genes for hereditary hearing loss in Middle
Eastern families. Genome Biol 2011;12(9):R89.
[6] Albert S, Blons H, Jonard L, et al. SLC26A4 gene is frequently involved in non-
syndromic hearing impairment with enlarged vestibular aqueduct in Caucasian
populations. Eur J Hum Genet 2006;14(6):773–9.
[7] Everett LA, Glaser B, Beck JC, et al. Pendred syndrome is caused by mutations in a
putative sulphate transporter gene (PDS). Nat Genet 1997;17(4):411–22.
[8] Brock PR, Knight KR, Freyer DR, et al. Platinum-induced ototoxicity in children: a
consensus review on mechanisms, predisposition, and protection, including a new
International Society of Pediatric Oncology Boston ototoxicity scale. J Clin Oncol
2012;30(19):2408–17.
[9] Zhang J, Wang P, Han B, et al. Newborn hearing concurrent genetic screening for
hearing impairment—a clinical practice in 58,397 neonates in Tianjin. China Int J
Pediatr Otorhinolaryngol 2013;77(12):1929–35.
[10] Karanja BW, Oburra HO, Masinde P, et al. Risk factors for hearing loss in children
following bacterial meningitis in a tertiary referral hospital. Int J Otolaryngol
2013;2013:354725.
[11] Chaleshtori MH, Farhud D, Patton M. Congratulation to Margaret Chan familial and
sporadic GJB2-related deafness in Iran: review of gene mutations. Iran J Public
Health 2007;36(1):1–14.
[12] Lindner TH, Hoﬀmann K. easyLINKAGE: a PERL script for easy and automated
two-/multi-point linkage analyses. Bioinformatics 2005;21(3):405–7.
[13] Thiele H, Nurnberg P. HaploPainter: a tool for drawing pedigrees with complex
haplotypes. Bioinformatics 2005;21(8):1730–2.
[14] Dehkordi FA, Rashki A, Bagheri N, et al. Study of VSX1 mutations in patients with
keratoconus in southwest Iran using PCR-single-strand conformation poly-
morphism/heteroduplex analysis and sequencing method. Acta Cytol
2013;57(6):646–51.
[15] Yazdanpanahi N, Chaleshtori MH, Tabatabaiefar MA, et al. Two novel SLC26A4
mutations in Iranian families with autosomal recessive hearing loss. Int J Pediatr
Otorhinolaryngol 2012;76(6):845–50.
[16] Tekin M, Akcayoz D, Comak E, et al. Screening the SLC26A4 gene in probands with
deafness and goiter (Pendred syndrome) ascertained from a large group of students
of the schools for the deaf in Turkey. Clin Genet 2003;64(4):371–4.
[17] Walsh T, Abu Rayan A, Abu Sa'ed J, et al. Genomic analysis of a heterogeneous
Mendelian phenotype: multiple novel alleles for inherited hearing loss in the
Palestinian population. Hum Genomics 2006;2(4):203–11.
[18] Anwar S, Riazuddin S, Ahmed ZM, et al. SLC26A4 mutation spectrum associated
with DFNB4 deafness and Pendred's syndrome in Pakistanis. J Hum Genet
2009;54(5):266–70.
[19] Dossena S, Nofziger C, Brownstein Z, et al. Functional characterization of pendrin
mutations found in the Israeli and Palestinian populations. Cell Physiol Biochem
2011;28(3):477–84.
[20] Fugazzola L, Cirello V, Dossena S, et al. High phenotypic intrafamilial variability in
patients with Pendred syndrome and a novel duplication in the SLC26A4 gene:
clinical characterization and functional studies of the mutated SLC26A4 protein.
Eur J Endocrinol 2007;157(3):331–8.
[21] Tsukada K, Nishio SY, Hattori M, et al. Ethnic-speciﬁc spectrum of GJB2 and
SLC26A4 mutations: their origin and a literature review. Ann Otol Rhinol Laryngol
2015;124(1):61S–76S.
F. Azadegan-Dehkordi et al. Am J Otolaryngol xxx (xxxx) xxx–xxx
7
